The S&P 500 logged a sixth straight record close yesterday, driven primarily by the rally in technology stocks. The tech-heavy Nasdaq has also been witnessing an uptrend. A better-than-expected…
October jobs report and the Fed’s announcement earlier this week that it will begin tapering its asset-purchase program, which reflects its confidence in the economy’s ability to handle lingering issues, should keep the market upbeat near term.
While rising inflation and supply chain issues remain concerns, Fed Chairman Jerome Powell’s reiteration of the word ‘transitory’ regarding inflation brought some relief.
Given this backdrop, Wall Street Analysts expect fundamentally sound stocks Lufax Holding Ltd (LU – Get Rating), Organogenesis Holdings Inc. (ORGO – Get Rating), LexinFintech Holdings Ltd. (LX – Get Rating), and Brightcove Inc. (BCOV – Get Rating) to deliver significant upside in the near term.
Headquartered in Shanghai, China, LU is a technology-empowered personal financial services platform. It offers loan products, including unsecured and secured loans, as well as consumer finance loans.
On June 28, 2021, LU announced its partnership with Schroders Singapore, a wholly-owned subsidiary of Schroders, an asset management company, to co-innovate digital wealth solutions in Southeast Asia. Lily Choh, Country Head, Schroders Singapore, said, “We are very excited to be embarking on this journey with LUI who is in the forefront of digital and technological developments.”
LU’s total income increased 17.3% year-over-year to $2.3 billion in the second quarter, ended June 30, 2021. Its net profit was $732 million, up 53.2% year-over-year. Its net margin came in at 31.9% compared to 24.4% in the year-ago period.
Analysts expect LU’s revenue and EPS to increase 19.8% and 12.6%, respectively, year-over-year to $9.56 billion and $1.07 in its fiscal 2021. In addition, it surpassed the Street’s EPS estimates in each of the trailing four quarters.
The stock is currently trading 1.7% above its 52-week price low of $6.06, which it hit on November 5, 2021. Wall Street analysts expect the stock to hit $10.47 in the near term, which indicates a potential 70% upside.
ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets in the United States. ORGO is headquartered in Canton, Mass.
On October 27, 2021, ORGO announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and NuShield® product lines would be showcased at the…
Continue reading at STOCKNEWS.com